Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Prevails On PDUFA Antibiotic Incentive As House Vote Nears

This article was originally published in The Pink Sheet Daily

Executive Summary

House is expected to vote on the reconciled FDA user fee bill June 20. Negotiators picked Senate GAIN language, including its less prescriptive qualifying pathogen definition.

You may also be interested in...

Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t

Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.

GPhA’s Deficit Reduction Proposals Focus On Medicare Low-Income Subsidy, REMS Policies

In letters to congressional leaders, generic drug trade group outlines six proposals that it says would save the government billions of dollars and lessen the impact of sequestration cuts.

Antibiotic Exclusivity: Which Vision Will GAIN Upper Hand In FDA List-making?

Industry presenters tell FDA a broad list of potential diseases will attract more developer interest, but advocacy groups push for more targeted criteria during a public hearing on the new exclusivity incentive.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts